Tai Sandi See - 05 Feb 2024 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Development Officer
Signature
/s/ Jenny Robertson, attorney-in-fact
Issuer symbol
LXEO
Transactions as of
05 Feb 2024
Net transactions value
$0
Form type
3
Filing time
06 Feb 2024, 17:58:54 UTC
Next filing
10 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LXEO Common Stock 16,625 05 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LXEO Employee Stock Option (right to buy) 05 Feb 2024 Common Stock 64,189 $12.72 Direct F2
holding LXEO Employee Stock Option (right to buy) 05 Feb 2024 Common Stock 30,000 $14.48 Direct F3
holding LXEO Employee Stock Option (right to buy) 05 Feb 2024 Common Stock 69,750 $17.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2 25% of the shares underlying the option vest and become exercisable on October 30, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3 25% of the shares underlying the option vest and become exercisable on January 5, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F4 25% of the shares underlying the option vest and become exercisable on February 2, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.